Sarepta Q1 GAAP EPS $2.88 vs loss of $4.60; siRNA pipeline shows early positive data

Sarepta Therapeutics, Inc.

2026-Q1 EPS reported $2.88 revenue$730,803,000

Net product revenue $330.5M (ELEVIDYS $102.0M, PMO $228.6M); total rev $730.8M (-2% YoY).
GAAP net income $331.0M vs loss of $447.5M; non-GAAP net income $385.4M.
siRNA candidates SRP-1001 (FSHD1) and SRP-1003 (DM1) show dose-dependent exposure and biomarker effects in Phase 1/2.
sNDA submitted to convert AMONDYS 45 and VYONDYS 53 to traditional approval; FY guidance reaffirmed $1.2-1.4B revenue.
ENDEAVOR Cohort 8 dosing underway for non-ambulatory DMD with sirolimus pretreatment; $40M milestone from Japan.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Sarepta Therapeutics, Inc. reported first quarter 2026 results: revenue $330.5 million, net income $331.0 million, EPS $2.88. Guidance reaffirmed.

Period: first quarter 2026
Revenue: $330.5 million
Net income: $331.0 million
EPS: $2.88
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments – Net product revenues for the first quarter 2026 totaled $330.5 million, consisting of $102.0 million of ELEVIDYS net product revenue and $228.6 million of PMO net product revenues – Achieved GAAP and non-GAAP operating income of $358.4 million and $397.7 million for the first quarter 2026, respectively

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Sarepta Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-208966

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.